ZYDUSLIFE:NSE:NSE-Zydus Lifesciences Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 866.9

Change

0.00 (0.00)%

Market Cap

USD 891.92B

Volume

3.29M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-223.90 (-4.08%)

USD 1,533.20B
CIPLA:NSE Cipla Limited

-30.55 (-2.16%)

USD 1,164.75B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-52.95 (-1.61%)

USD 1,092.48B
MANKIND:NSE Mankind Pharma Ltd

-67.75 (-2.76%)

USD 1,000.40B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-22.05 (-1.99%)

USD 953.29B
LUPIN:NSE Lupin Limited

-48.00 (-2.44%)

USD 925.89B
AUROPHARMA:NSE Aurobindo Pharma Limited

-11.30 (-1.02%)

USD 674.02B
ABBOTINDIA:NSE Abbott India Limited

-111.70 (-0.38%)

USD 653.01B
ALKEM:NSE Alkem Laboratories Limited

-128.20 (-2.65%)

USD 583.68B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-57.65 (-3.84%)

USD 434.87B

ETFs Containing ZYDUSLIFE:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.98% 69% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.98% 69% C- 70% C-
Trailing 12 Months  
Capital Gain -13.87% 30% F 45% F
Dividend Return 0.30% 23% F 25% F
Total Return -13.57% 30% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 41.25% 75% C 59% D-
Dividend Return 41.75% 75% C 59% D-
Total Return 0.50% 49% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 37.75% 67% D+ 65% D
Risk Adjusted Return 110.59% 96% N/A 89% A-
Market Capitalization 891.92B 93% A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector